Patent ID: 6323237
Filing Date: 2001-11-27
Classification: A23L,A23V,A61K,A61P,C07B,C07C,C07D

Abstract:
A method of treating a patient for a neuro-degenerative disorder selected from the group consisting of those involving inability to metabolise glucose inhibition of pyruvate dehydrogenase memory loss in aging, neurotoxic peptides or proteins, and genetic abnormality comprising administering to that patient a therapeutically effective amount of one or more of D-.beta.-hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D-.beta.-3-hydroxybutyric acid or acetoacetate, such as to elevate the patient's blood level of ketone bodies, defined as the sum total of D-.beta.-hydroxybutyric acid and acetoacetate, to a therapeutic level effective to treat the disorderwherein when a metabolic precursor is administered it is not hydroxybutyryl carnitine.